AbbVie addresses hep C cash flow problems

Viekira Pak
AbbVie Australia has announced the launch of a program to support timely patient access to their Hepatitis C medications VIEKIRA PAK and VIEKIRA PAK-RBV (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets with or without ribavirin) via community pharmacy. The two therapies are now available on the PBS for the treatment of genotype 1 chronic hepatitis C.1-3.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Have you had a look at the new AJP Discussion Forum yet?
Next 'Mixed bag' Budget